Abstract Background and Objectives Monomethyl auristatin E (MMAE, a cytotoxic agent),
upon releasing from valine-citrulline-MMAE (vc-MMAE) antibody-drug conjugates (ADCs), is …

Monomethyl auristatin E (MMAE) is one of the most commonly used payloads for developing
antibody–drug conjugates (ADC). However, limited studies have comprehensively …

An integrated pharmacokinetics (PK) model that simultaneously describes concentrations of
total antibody (Tab) and antibody‐conjugated monomethyl auristatin E (acMMAE) following …

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the target
specificity of an antibody with the potency of a chemotherapeutic. This therapeutic strategy …

Purpose A semi-mechanistic multiple-analyte population pharmacokinetics (PK) model was
developed to describe the complex relationship between the different analytes of …

Over the past two decades, antibody-drug conjugates (ADCs) have emerged as a promising
class of drugs for cancer therapy and have expanded to nononcology fields such as …

Antibody drug conjugates (ADC), in which small molecule cytotoxic agents are non-
specifically linked to antibodies, can enable targeted delivery of chemotherapeutics to tumor …

The main objective of this work was to understand and mathematically characterize the
cellular disposition of a tool antibody-drug conjugate (ADC), trastuzumab–valine-citrulline …

To build a multiscale mechanism based pharmacokinetic–pharmacodynamic (PK/PD) model
for antibody drug conjugates (ADCs), using brentuximab-vedotin as an example, for …

Enfortumab vedotin is an antibody–drug conjugate (ADC) comprised of a Nectin-4–directed
antibody and monomethyl auristatin E (MMAE), which is primarily eliminated through P …